 | • レポートコード：MRC2304E018 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、233ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に171.22百万ドルであった世界の患者由来異種移植片/PDXモデル市場規模が、2022年に194.97百万ドルに達し、2027年には378.32百万ドルまで年平均14.12%で成長すると予測しています。当レポートは、患者由来異種移植片/PDXモデルの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（マウス、ラット）分析、エンドユーザー別（学術＆研究機関、受託研究機関（CRO）、製薬＆バイオテクノロジー企業）分析、腫瘍種類別（消化器腫瘍、婦人科腫瘍、血液腫瘍、その他）分析、用途別（がん基礎研究、バイオマーカー解析、前臨床薬開発）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめています。なお、当書には、Abnova Corporation、Champions Oncology, Inc.、Charles River Laboratories、Envigo、EPO Berlin-Buch GmbH、Explora BioLabs、Genesis Biotechnology Group、Hera BioLabs、Oncodesign、Pharmatest Servicesなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の患者由来異種移植片/PDXモデル市場規模：種類別 - マウスモデルの市場規模 - ラットモデルの市場規模 ・世界の患者由来異種移植片/PDXモデル市場規模：エンドユーザー別 - 学術＆研究機関における市場規模 - 受託研究機関（CRO）における市場規模 - 製薬＆バイオテクノロジー企業における市場規模 ・世界の患者由来異種移植片/PDXモデル市場規模：腫瘍種類別 - 消化器腫瘍モデルの市場規模 - 婦人科腫瘍モデルの市場規模 - 血液腫瘍モデルの市場規模 - その他腫瘍種類の市場規模 ・世界の患者由来異種移植片/PDXモデル市場規模：用途別 - がん基礎研究における市場規模 - バイオマーカー解析における市場規模 - 前臨床薬開発における市場規模 ・世界の患者由来異種移植片/PDXモデル市場規模：地域別 - 南北アメリカの患者由来異種移植片/PDXモデル市場規模 アメリカの患者由来異種移植片/PDXモデル市場規模 カナダの患者由来異種移植片/PDXモデル市場規模 ブラジルの患者由来異種移植片/PDXモデル市場規模 … - アジア太平洋の患者由来異種移植片/PDXモデル市場規模 日本の患者由来異種移植片/PDXモデル市場規模 中国の患者由来異種移植片/PDXモデル市場規模 インドの患者由来異種移植片/PDXモデル市場規模 韓国の患者由来異種移植片/PDXモデル市場規模 台湾の患者由来異種移植片/PDXモデル市場規模 … - ヨーロッパ/中東/アフリカの患者由来異種移植片/PDXモデル市場規模 イギリスの患者由来異種移植片/PDXモデル市場規模 ドイツの患者由来異種移植片/PDXモデル市場規模 フランスの患者由来異種移植片/PDXモデル市場規模 ロシアの患者由来異種移植片/PDXモデル市場規模 … - その他地域の患者由来異種移植片/PDXモデル市場規模 ・競争状況 ・企業情報 |
The Global Patient-Derived Xenograft/PDX Model Market size was estimated at USD 171.22 million in 2021 and expected to reach USD 194.97 million in 2022, and is projected to grow at a CAGR 14.12% to reach USD 378.32 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Patient-Derived Xenograft/PDX Model to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Mice Models and Rat Models.
Based on End User, the market was studied across Academic & Research Institutions, Contract Research Organizations (CROs), and Pharmaceutical & Biotechnology Companies.
Based on Tumor Type, the market was studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Other Tumor Models, Respiratory Tumor Models, and Urological Tumor Models.
Based on Application, the market was studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Patient-Derived Xenograft/PDX Model market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Patient-Derived Xenograft/PDX Model Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Patient-Derived Xenograft/PDX Model Market, including Abnova Corporation, Champions Oncology, Inc., Charles River Laboratories, Envigo, EPO Berlin-Buch GmbH, Explora BioLabs, Genesis Biotechnology Group, Hera BioLabs, Oncodesign, Pharmatest Services, SR Corporation, THE JACKSON LABORATORY, Urosphere, WuXi AppTec, and Xentech.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Patient-Derived Xenograft/PDX Model Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Patient-Derived Xenograft/PDX Model Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Patient-Derived Xenograft/PDX Model Market?
4. What is the competitive strategic window for opportunities in the Global Patient-Derived Xenograft/PDX Model Market?
5. What are the technology trends and regulatory frameworks in the Global Patient-Derived Xenograft/PDX Model Market?
6. What is the market share of the leading vendors in the Global Patient-Derived Xenograft/PDX Model Market?
7. What modes and strategic moves are considered suitable for entering the Global Patient-Derived Xenograft/PDX Model Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for personalized medicine
5.1.1.2. Oncology and preclinical development
5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
5.1.2. Restraints
5.1.2.1. High cost of personalized PDX model
5.1.3. Opportunities
5.1.3.1. Rising demand for humanized PDX Model
5.1.3.2. Growth in pharma R&D
5.1.4. Challenges
5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
5.2. Cumulative Impact of COVID-19
6. Patient-Derived Xenograft/PDX Model Market, by Type
6.1. Introduction
6.2. Mice Models
6.3. Rat Models
7. Patient-Derived Xenograft/PDX Model Market, by End User
7.1. Introduction
7.2. Academic & Research Institutions
7.3. Contract Research Organizations (CROs)
7.4. Pharmaceutical & Biotechnology Companies
8. Patient-Derived Xenograft/PDX Model Market, by Tumor Type
8.1. Introduction
8.2. Gastrointestinal Tumor Models
8.3. Gynecological Tumor Models
8.4. Hematological Tumor Models
8.5. Other Tumor Models
8.6. Respiratory Tumor Models
8.7. Urological Tumor Models
9. Patient-Derived Xenograft/PDX Model Market, by Application
9.1. Introduction
9.2. Basic Cancer Research
9.3. Biomarker Analysis
9.4. Preclinical Drug Development
10. Americas Patient-Derived Xenograft/PDX Model Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abnova Corporation
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Champions Oncology, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Charles River Laboratories
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Envigo
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. EPO Berlin-Buch GmbH
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Explora BioLabs
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Genesis Biotechnology Group
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Hera BioLabs
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Oncodesign
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Pharmatest Services
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. SR Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. THE JACKSON LABORATORY
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Urosphere
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. WuXi AppTec
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Xentech
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing